|Bid||156.13 x 1000|
|Ask||159.00 x 2200|
|Day's Range||155.01 - 162.48|
|52 Week Range||48.57 - 176.40|
|Beta (5Y Monthly)||0.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||136.35|
Following the announcement of the agreement to pass the historic stimulus bill, we look into four MedTech stocks that stand to gain from the same.
Today's Stock Idea: Teladoc (TDOC)One of the best performing stocks of 2020 -- behind Vir Biotech (VIR) and Zoom Video Communications (ZM) \-- traders took profit in Teladoc Tuesday. The stock was down about 5% following news at the open from digital healthcare company VitalTech it will partner with AT&T (T) to offer "60 days of free telehealth services through the VitalCare® platform to business customers like hospitals."Teladoc shares fell about 2% as the VitalTech press release hit newswires, then rebounded from below the $157 level. Later in Tuesday's session, when that $157 level came back into play, volume spiked as shares fell to a low under $153. Traders may have attributed the weakness in Teladoc shares to the fact a seeming competitor for its telehealth/digital healthcare services was partnering with a major consumer-related corporation like AT&T. In addition, with Teladoc shares up about 82% so far in 2020 -- especially with the S&P 500 down 19% year to date -- traders may have viewed the VitalTech news as an opportunity to lock in some gains in Teladoc.See more from Benzinga * Benzinga Pro's Top 5 Stocks To Watch For Wed., Mar. 11, 2020: TDOC, GNMK, HLT, MEET, AYTU(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
Prior to the outbreak of the coronavirus from China, receiving healthcare through teleconferencing might have sounded like a fringe idea. Today, patients are taking this option seriously. As a result, Teladoc (NYSE:TDOC) stock is worth a second look if you're considering a telehealth play.Source: Piotr Swat / Shutterstock.com In fact, virtual care has already become a popular alternative to traditional face-to-face healthcare. Teladoc was an early mover in this space. The price of TDOC stock has risen, but there's still room for growth while the public remains reluctant to venture into hospitals and doctors' offices. A Novel IdeaThe idea of healthcare through teleconferencing might have seemed outlandish to people just a few months ago. Now, the social-distancing trend has taken hold of America and the world. Many people choose to avoid leaving the house. Plus, they know that clinics and hospitals are breeding grounds for diseases.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTeladoc fulfills people's desire to receive healthcare services without having to leave their homes. The company can't provide every service, but you might be surprised at what they can offer. Teladoc's offerings run the gamut from expert medical services to mental health services, and the company claims that "After a visit, 92 percent of patients reported resolution." * 7 U.S. Stocks to Buy on Coronavirus Weakness On Teladoc's busier days, the company has facilitated literally thousands of patient visits. Skeptics might wonder about the quality of the virtual visits, however. That objection is understandable. Yet, the data surrounding this might surprise you.As reported via Teladoc, "62% of patients reported the quality of virtual video visits was no different from that of office visits." That might surprise you. But then, consider the idea of not having to sit for an hour in a waiting room. Think about being able to stay in the comfort of your own home during a doctor's visit.It has also been observed that "21% of patients thought virtual visits' overall quality was better." That number could certainly increase if clinics and hospitals become more crowded and wait times become longer. Avoiding crowds of people could become a high priority because of the coronavirus. Demand Is SpikingParticipating in virtual healthcare appears to be on the rise. During the second week of March, Teladoc's volume of patient visits was 50% greater than it had been in the prior week. Astonishingly, the volume has reached as high as 15,000 daily requested visits.Experts and regulators seem to be on board with this growing trend. For example, the Centers for Disease Control and Prevention explicitly acknowledged that "Leveraging telemedicine whenever possible is the best way to protect patients and staff from COVID-19."Moreover, the U.S. House of Representatives has passed an emergency spending bill that, in crisis situations, permits Medicare reimbursement for tele-health.Since Teledoc specializes in facilitating virtual healthcare, investors should consider TDOC stock as representative of an emerging trend that's likely to continue its exponential growth. The Final Word on TDOC StockThe coronavirus outbreak has made "social distancing" part of the American and global culture. It is likely to persist long past this year. Many patients don't seem to mind receiving healthcare remotely. Some even prefer it. Therefore, Teladoc stockholders should be positioned well to capitalize on a healthcare shift that's most likely just getting started.Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system -- with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the "Master Key" to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * America's Richest ZIP Code Holds Wealth Gap Secret * 10 Stocks to Buy That Will Benefit From Coronavirus Mayhem * 5 Bank Stocks to Buy Now Because This Isn't 2008 Again * 12 Stocks to Buy That Are Already Positive The post Teladoc Stock Will Power Higher in the New Age of Healthcare appeared first on InvestorPlace.
Many of the large insurers have moved into the telemedicine arena. While not a large part of their business yet, I believe it will grow much larger, with coronavirus acting as an accelerant to this new business line, explains Eddy Elfenbein, editor of Growth Stock Advisor.
The text of the deal reached late last night in the Senate to cushion the impact of the Covid-19 pandemic remains under wraps, but details released Wednesday suggest it could have an impact on key areas of the health-care sector. The Senate draft of the bill includes substantial funding for telemedicine options, extra Medicare payments for the treatment of Covid-19 patients, advances for hospitals on upcoming Medicare payments, and a postponement of a scheduled cut in Medicaid payments to certain hospitals. “We boost telehealth services, we boost payments to health care providers and hospitals to ensure they have the resources to care for patients and we remove restrictions for anybody with health savings accounts,” said Iowa Sen. Chuck Grassley, chair of the Senate Finance Committee, in a statement.
Short sellers have had a pretty good run since mid-February, with U.S. stocks down significantly almost across the board. However, a handful of stocks have had big runs in recent weeks, and S3 Partners analyst Ihor Dusaniwsky said some of those stocks could soon be short squeeze candidates.Given the volatility and unpredictability of the market, huge up days like Tuesday can catch short sellers off guard, potentially triggering a wave of short covering. Dusaniwsky said there are only six U.S. stocks that have generated more than $100 million in net losses for short sellers over the past month, and two of them have been particularly costly for short sellers."While these losses and the relative cheap stock borrow rates preclude me from saying these are all immediate short squeeze candidates, there are several that may get squeezed sooner rather than later," Dusaniwsky said.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Short Squeeze Candidates Here are the six stocks that have generated the most mark-to-market losses for short sellers since Feb. 19: * Zoom Video Communications Inc (NASDAQ: ZM), -$710.1 million. * Teladoc Health Inc (NYSE: TDOC), -$703.4 million. * Regeneron Pharmaceuticals Inc (NASDAQ: REGN), -$146 million. * Moderna Inc (NASDAQ: MRNA), -$132 million * Gilead Sciences, Inc. (NASDAQ: GILD), -$125.7 million. * Domino's Pizza, Inc. (NYSE: DPZ), -$101.3 million.Dusaniwsky said short covering could start happening when markets begin to rebound, and the stocks on this list could be among the first to get squeezed.Benzinga's Take Some of these stocks, such as Zoom, Teladoc and Dominos, have actually benefited from the quasi-quarantine situation in the U.S. economy at the moment. When the broader market and economy start to get back to normal, traders should remember these red-hot stocks may actually underperform during the recovery.Do you agree with this take? Email email@example.com with your thoughts.Related Links:7 ETFs To Buy In A Recession The Most Shorted ETFs Amid The Coronavirus Market CrashLatest Ratings for ZM DateFirmActionFromTo Mar 2020Morgan StanleyMaintainsEqual-Weight Mar 2020NeedhamInitiates Coverage OnBuy Mar 2020JP MorganMaintainsOverweight View More Analyst Ratings for ZM View the Latest Analyst RatingsSee more from Benzinga * Benzinga CEO Talks Hedging Bets, Dividend Plays On PreMarket Prep(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
For his "Executive Decision" segment on the Mad Money program Monday evening, Jim Cramer checked back in with Jason Gorevic, CEO of Teladoc Health , the telemedicine provider with shares up 18% in Monday's session. Gorevic said the U.S. healthcare system is under strain and Teladoc is doing everything it can to help. The company is offering virtual Covid-19 clinics to train healthcare workers on proper procedures and is bringing their virtual services to hospitals to help keep on-site personnel out of harm's way.
The demand for virtual healthcare services like Teladoc Health, Inc. (NYSE: TDOC) has been shifted permanently by the novel coronavirus (COVID-19) pandemic, the company's CEO Jason Gorevic told CNBC Mad Money host Jim Cramer on Monday.What Happened "[We're] on the verge of a new era for virtual care in the health-care system," Gorevic said, as reported by CNBC."We're certainly seeing a significant increase in volume, and I didn't exactly expect the president to be talking at a White House press briefing about telehealth.""If you'd asked me that a few months ago, I would have said that's pretty unlikely," Gorevic added.President Donald Trump earlier this month announced that Medicare recipients would be able to access telehealth services at no additional costs during the COVID-19 pandemic.Why It Matters Teladoc stock is up 100% year-till-date as demand for telecommunications services has increased.With 46,442 confirmed cases of the coronavirus in the United States, healthcare infrastructure is overwhelmed with a shortage of protective gear for healthcare workers.Without the necessary protective gears including masks, gowns, and eyewear, doctors, nurses, paramedics, and other workers risk being infected with the virus themselves. This has led to authorities recommending increased use of telehealth services to curb the spread of the virus.Price Action Teladoc's shares closed 17.77% higher at $167.44 on Monday. The shares traded another 5.11% higher at $176 in the after-hours session.See more from Benzinga * Robinhood Offers Credit To Users Affected By Massive Outage * Tesla Has Already Delivered 1,000 Ventilators To Help Hospitals Fight Pandemic, California Governor Says * Google Surveys Users For Coronavirus Symptoms To Help Researchers Forecast Spread(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
(Bloomberg Opinion) -- Telemedicine, long hyped as a more efficient approach to health care, is finally taking off.People who suspect they’re suffering from Covid-19 symptoms are being told to self-isolate. But they also need to seek medical advice. Many are turning towards telemedicine providers, who eliminate the need to leave home by connecting the potentially ill with medical professionals in a telephone or video call. For healthcare providers, a remote consultation is considerably more cost effective (and safer) than an in-person visit.Telemedicine has for years promised a great deal, but previously delivered very little. All of a sudden it looks like it has genuine potential. French firm Doctolib SAS said last week that it had seen an 18-fold jump in the number of video consultations in the past month. U.S. health insurers have meanwhile agreed to cover coronavirus-related telemedicine, while the federal government has made it easier for Medicare recipients to use.Investors are keen on buying into an industry that the market leader, Teladoc Health Inc., estimates could be worth $10 billion in annual U.S. revenue. Shares in Teladoc, the sector’s only publicly traded firm of note, have doubled in value since the start of the year – the S&P 500 is down about 30% in the same period.With a $12 billion market valuation, Teladoc trades on 16 times predicted 2020 sales, according to Bloomberg data. That would make it the most highly valued stock in a basket of hot software companies compiled by Jefferies analysts David Windley and Ben Flox. Even tech darling ServiceNow Inc., a cloud computing firm, trades at 10 times expected sales. Small wonder analysts have been revising down their recommendations on Teladoc stock.Superficially, the conditions are ripe for matching investment capital with an industry that needs to grow. When Tesla Inc.’s stock enjoyed a similar jump in January and February, the electric vehicle manufacturer did an opportunistic share sale. But things aren’t quite so simple for the telemedicine industry.Volatile markets make it hard to see how Teladoc, whose shares have seen 20% swings, could sell equity or one of its rivals could raise money by going public. Venture capital firms are also targeting resources on the defense of existing investments rather than seeking out new ones. To meet the surging demand effectively, they likely need that money.Questions over where telemedicine’s profitability will settle may also make investors pause. As with any new sector, first-mover advantages may be eroded over time by competition. New entrants have been emerging fast, with venture capital piling into the burgeoning health-tech sector. In 2018, $895 million was invested in telehealth startups, according to PitchBook data.While Teladoc’s share-price surge is comparable to Tesla’s, its business model is more akin to Uber’s: it’s essentially a two-way marketplace. The value resides partly in the software that poses questions to patients to ensure they’re directed to the most suitable physician. The main barrier to entry is signing up enough doctors to attract patients, and (although less so today) enough patients to use the service.In tech, the usual method of addressing such problems is to throw money at them — in this case, by providing generous financial incentives to both sides of the market to sign up. As Uber, whose software connects riders to the nearest driver, has found, fights to outspend rivals may be best avoided. The ride-hailing company sold regional businesses to well-capitalized competitors in India, China and southeast Asia — cashing out of markets where it lacks scale instead of getting into price wars in the hope of eventually emerging as the dominant player.The need for capital is underscored by the operational challenges raised by Covid-19. Providers are still struggling to enlist sufficient doctors to meet demand, and are facing tech issues too, CNBC reported last week. Doctolib has an advantage, since it already has a database of doctors from its original business arranging medical appointments more efficiently.The industry has an opportunity to lessen the strain on the global health system. But whether it can overcome financial and operational constraints to make a significant difference to the current crisis remains to be seen.This column does not necessarily reflect the opinion of Bloomberg LP and its owners.Alex Webb is a Bloomberg Opinion columnist covering Europe's technology, media and communications industries. He previously covered Apple and other technology companies for Bloomberg News in San Francisco.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
While the broad market continues to struggle, investors are embracing shares of companies that are perceived to benefit from the growing number of people in the U.S. and around the world who are working from home.
Most investors are rightfully cautious during this market sell-off. The full economic effects of the COVID-19 pandemic remain to be seen, but what is certain right now is it has already led to a global economic slowdown.But all this fear doesn't mean there aren't opportunities for investors on the long side. One such stock I like right now is Teladoc Health Inc (NYSE: TDOC).The coronavirus outbreak has everybody concerned about their health. Employers are increasingly requesting their staff to work from home and avoid public places.Telehealth is a sector focused on providing medical services via digital communication channels. As an example: an individual might have the flu or a sinus infection but does not want to visit a doctor's office. This person can open the Telehealth program on their mobile/desktop device and speak directly with a licensed medical professional.The benefits to a customer are incredible. Virtual doctor visits are a lot cheaper ($45 vs $472 for the average claim, according to Teladoc), they save time by avoiding travel, and they protect others by not infecting anyone in the waiting/treatment rooms.The U.S. Healthcare Cost Dilemma The U.S. has the world's highest healthcare cost per capita ($10,586/year). The average cost in wealthy, developed countries is $5,287. On top of that, the U.S. spends the most on administrative costs per capita ($843/year, triple that of the second most expensive) while spending the second-least on long-term healthcare (preventive).With healthcare costs being that far above the second-most expensive country, you'd expect it to be the leader in terms of quality as well. But that's not necessarily the case.Who Will Dominate The Telemedicine Market? Providing virtual care is great, but both doctors and insurers don't want to deal with dozens of different platforms. I believe there will only be one or two companies that will handle the vast majority of telehealth services.I believe Teladoc will be that leader. With over 50 million active users, they currently have the largest market share of any telehealth provider.When I first recommended this company to my subscribers on March 12, shares were trading at $58. As of this writing it's at $159, and I believe there still is a lot more upside ahead.The management at Teladoc has proven to be very effective at executing a sophisticated corporate strategy that focuses on providing the full range of services through internal product development and acquisitions of specialized market leaders.The coronavirus outbreak is just another catalyst to support this stock. Vice President Mike Pence stated that companies have agreed to cover telemedicine through platforms like Teladoc.The company has nearly tripled in value over the past 12 months and has a year-to-date performance of 64.4%. The current P/E ratio could be considered overvalued based on current revenue, yet can also be considered a steal considering future growth potential. Based on growth projections, I'm leaning towards the latter.If you'd like more of these ideas, please click here to join me for an upcoming webinar that will go over how to protect your portfolio, making profitable investments during this downturn, and tools to help you systemize your investing approach. See more from Benzinga * David Tepper Says There's 'Nothing Wrong With Nibbling A Little Bit' For Now * Roku Vs. Netflix: Needham's Laura Martin Sees A Clear Quarantine Winner * Private Equity Focusing On Primary Care Practices For Their Value And Social Impact(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Investors should keep their "eyes on the prize," but avoid large stock purchases at current levels because there is still plenty of room for "more ugly headlines," Jim Cramer said on Thursday.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Business Tools Investors should avoid any temptation to "buy sizably" with the market trading near multi-year lows, Cramer said on "Mad Money." The unfortunate reality is the coronavirus pandemic "may just be getting started" and investors should focus on companies that can thrive in the current environment.Businesses need to continue working and as it turns out many people are realizing that operating from home isn't all that bad. In fact, all the commuting to and from work and the associated carbon emissions has proven to be "unnecessary for millions of people."Two big winners from this trend include Cisco Systems, Inc. (NASDAQ: CSCO), which operates Webex, and Zoom Video Communications Inc (NASDAQ: ZM)."We have discovered that working from home is actually a pretty good way to do business because video conferencing software has gotten so good," Cramer said.Remote Services People who need to see a doctor for regular health checkups and non-coronavirus related illnesses could embrace remote services, such as Teladoc Health (NYSE: TDOC). The company allows for patients to connect with a doctor through a mobile device and the Trump administration authorized this week an expansion of services that can be offered."Anything that lets you see a doctor without actually going to the doctor's office is a winner during this pandemic," he said. "It's cheaper, it's more convenient, and it's a heck of a lot safer."Photo courtesy of Zoom.See more from Benzinga * Teladoc, Ping Identity, Emergent Biosolutions: Portfolio Manager Shares Stock Picks After Monday's Carnage * Zoom Video Investors Cheer Q4 Results, Analysts Stay Conservative(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.